文献速递浆细胞疾病

单克隆蛋白尿可预测游离轻链比值≥100的无症状多发性骨髓瘤患者的进展风险

Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100.
PubMed 文献 · Leukemia · 2022-02-21

这项回顾性研究纳入822例无骨髓瘤定义事件(MDE)的无症状多发性骨髓瘤患者,其中120例游离轻链比值(FLCr)≥100,702例FLCr<100。FLCr≥100组按24小时尿单克隆蛋白(uMCP)排泄量分组,uMCP≥200 mg/24h组35例,<200 mg/24h组85例。结果显示uMCP≥200 mg/24h组2年进展至症状性多发性骨髓瘤或AL淀粉样变性的风险显著高于<200 mg/24h组(36.2% vs 13.5%,HR 2.79,95%CI 1.57-4.96,p<0.001)。

要点

  • FLCr≥100且uMCP≥200 mg/24h的无症状骨髓瘤患者2年进展风险为36.2%,显著高于uMCP<200 mg/24h组的13.5%。
  • 基线FLCr<100与FLCr≥100且uMCP<200 mg/24h的患者进展风险相似(log rank p=0.127)。
  • FLCr≥100时uMCP排泄增加是不良预后标志,作者指出应进行诊断性24小时尿液评估。

核心结论

  • 在FLCr≥100的无症状多发性骨髓瘤患者中,uMCP排泄≥200 mg/24h是不良预后标志,与更高的进展风险相关。
  • 作者指出,当FLCr是唯一的骨髓瘤定义事件时,进行诊断性24小时尿液评估可能有助于细化需要治疗的患者亚组。

研究设计与样本

  • 回顾性研究,纳入822例无骨髓瘤定义事件(除FLCr升高外)的无症状多发性骨髓瘤患者。
  • 其中FLCr≥100者120例,FLCr<100者702例;FLCr≥100组按24小时uMCP排泄量分为≥200 mg/24h(35例)和<200 mg/24h(85例)。

主要发现

  • uMCP≥200 mg/24h组2年进展至症状性多发性骨髓瘤或AL淀粉样变性的风险为36.2%,uMCP<200 mg/24h组为13.5%。
  • uMCP≥200 mg/24h组较<200 mg/24h组的进展风险HR为2.79(95%CI 1.57-4.96,p<0.001)。
  • 基线FLCr<100组与FLCr≥100且uMCP<200 mg/24h组的进展风险相似(log rank p=0.127)。

临床怎么用

  • 作者指出,当FLCr是唯一的骨髓瘤定义事件时,进行诊断性24小时尿液评估可能有助于细化需要治疗的患者亚组。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

A baseline involved to uninvolved free light chain ratio (FLCr) ≥100 with involved FLC ≥10 mg/dL is a multiple myeloma (MM)-defining event (MDE). However, multimeric light chain aggregates may contribute to increased FLC levels and impair renal light chain clearance. Therefore, we conducted a retrospective study to assess the association between urine monoclonal protein (uMCP) excretion and the risk of progression. We included 822 asymptomatic MM patients without MDE besides elevated FLCr (n=120 with FLCr ≥100, n=702 with FLC <100). Patients with a FLC ≥100 were grouped based on 24-hour uMCP excretion (≥200 mg/24h [n=35], <200 mg/24h [n=85]). The 2-year risk of progression to symptomatic MM or AL amyloidosis was significantly higher in patients with uMCP excretion ≥200 versus <200 mg/24h (36.2% versus 13.5%, respectively; HR 2.79, 95%CI 1.57-4.96, p<0.001). However, the progression risk was similar in patients with a baseline FLCr <100 versus FLC≥100 with uMCP <200 mg/24h (log rank p=0.127). We showed that increased uMCP excretion in the setting of a FLCr ≥100 is an unfavorable prognostic marker. This underscores the importance of conducting a diagnostic 24-hour urine assessment and may help refine the subset of patients warranting therapy if the FLCr is the only MDE.

来源:Leukemia,查看原文。版权归原作者所有。

引用

  1. Visram A, Rajkumar SV, Kapoor P, et al. Monoclonal proteinuria predicts progression risk in asymptomatic multiple myeloma with a free light chain ratio ≥100. Leukemia. 2022. PMID: 35190659. doi:10.1038/s41375-022-01529-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。